Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 13

Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity

Authors Barjaktarevic I, Kaner R, Buhr RG, Cooper CB

Received 13 August 2018

Accepted for publication 12 September 2018

Published 23 October 2018 Volume 2018:13 Pages 3511—3513

DOI https://doi.org/10.2147/COPD.S183736

Checked for plagiarism Yes

Editor who approved publication: Dr Richard Russell


Igor Barjaktarevic,1 Robert Kaner,2,3 Russell G Buhr,1,4 Christopher B Cooper1,5

1Division of Pulmonary and Critical Care, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2Division of Pulmonary and Critical Care, Weill Cornell Medicine, NY, USA; 3Department of Genetic Medicine, Weill Cornell Medicine, NY, USA; 4Department of Health Policy and Management, Fielding School of Public Health at UCLA, Los Angeles, CA, USA; 5Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Asthma and COPD present with multiple overlapping phenotypes,1–3 making a simplified diagnostic separation between the two disease states difficult. From a practical standpoint, the difficulty in differentiating between asthma and COPD has been a limitation and a foundation for criticism of large prospective trials.4 Multiple attempts to better define the population of patients with features of both diseases have been made,5,6 yet a common consensus about the best way to approach this problem is missing. Part of this problem relates to our reliance on oversimplified and relatively crude spirometric definitions of asthma and COPD7 and an incomplete understanding of how to interpret changes after bronchodilator administration. Imprecise definitions of the terms “bronchodilator responsiveness” and “reversibility” add to the confusion in the attempts to distinguish between COPD and asthma. Although the two terms are often used interchangeably in the published literature,8 and their difference may seem to be an issue of semantics, appropriately defining “bronchodilator responsiveness” and “reversibility” is essential for understanding the role of bronchodilator administration in the diagnostic workup of obstructive lung disease.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]